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a b s t r a c t
Two serine protease enzymes, subtilisin 309 and subtilisin 309-v, were used to digest brain homogenates
containing high levels of prion infectivity using mildly alkaline conditions to investigate prion decon-
tamination methods. To establish that PrPres infectivity was eliminated, we utilized the Rocky Mountain
Laboratory (RML) mouse-adapted scrapie model system for bioassay. Only one digestion condition (sub-
tilisin 309 at 138mAU/ml, 55 ◦C and 14h digestion time pH 7.9) was considered to be highly relevant
statistically (P<0.001) compared to control, with 52% of challenged mice surviving until the end of the
study period. In contrast, treatment of PrPres by autoclaving at 134 ◦C or treatment with hypochlorite at a
concentration of 20,000ppm completely protected mice from prionosis. Further, in vitro assays suggest
that potential proteolytic based PrPres decontamination methods must use high enzyme concentration,
pH values >9.0, and elevated temperatures to be a safely efficacious, thereby limiting applicability on
delicate surgical instruments and use in the environment.
Published by Elsevier B.V.
1. Introduction
Transmissible spongiform encephalopathies (TSEs) are progres-
sive diseases for which aberrantly folded prion proteins (PrPres)
appear to be the causative agent (Prusiner, 1982). Theuniquenature
of PrPres, the many unanswered questions regarding TSEs, and the
resistance of prions to decontamination,make containment of TSEs
problematic. As there are no effective treatments for prion diseases,
methods todecontaminate infected surfaces and sites are especially
important for managing TSEs.
A variety of methods have been tested for prion destruc-
tion (Fichet et al., 2004; McDonnell and Burke, 2003). The prion
decontamination methods currently suggested in The Biosafety
in Microbiological and Biomedical Laboratories manual (USDHHS,
2007), such as high concentrations of hypochlorite or 1NNaOH, are
inconvenient because of noxious or irritating fumes and in many
situations are not possible due to incompatibility with contami-
nated surfaces, materials, and equipment. Clearly, better methods
for decontamination of PrPres are needed.
∗ Corresponding author. Tel.: +1 970 266 6093; fax: +1 970 266 6157.
E-mail addresses: John.l.pilon@usda.gov (J.L. Pilon), Paul.b.nash@usda.gov
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In spite of the resistance of PrPres to proteolytic inactivation,
someproteolytic decontaminationmethods have been investigated
with variable success. Protease digestion and elimination of ELISA
or Western-blot immunoreactivity has been shown under a vari-
ety of conditions (Hui et al., 2004a, 2004b; Langeveld et al., 2003;
Tsiroulnikov et al., 2004; Mitsuiki et al., 2006; Rapp et al., 2006;
Scherbel et al., 2006; Muller-Hellwig et al., 2006). However, pro-
tease destruction of prions below in vitro assay detection limits
does not necessarily mean that PrPres has been reduced to levels
that are no longer infectious inmore sensitive bioassays; therefore,
methods investigating decontamination of infectious prions need
to be tested in vivo until better in vitro methods are developed and
validated (McLeod et al., 2004; Lawson et al., 2006).
Bioassays in live animals aremore sensitive, test actual infection,
are representative of natural infection, and can detect low-level
residual infectivity that may reside below the limit of detection of
traditional immunoassays. Experiments utilizing mouse bioassays
to investigate decontamination of PrPres material with proteinase
K (Jackson et al., 2005; Yakovleva et al., 2004), Properase (McLeod
et al., 2004), and Rapid Multi-Enzyme cleaner 3M (Lawson et al.,
2006), suggests that enzymatic approaches to PrPres contamination
is achievable. Although the references cited were somewhat suc-
cessful, the difficulty in achieving a robust PrPres decontamination
method is also revealed in the published data.
The enzymatic digestion methods presented in this paper were
used as an initial screen to test for economic feasibility, mild diges-
0166-0934/$ – see front matter. Published by Elsevier B.V.
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Table 1
Conditions for treatment of mouse-adapted scrapie brain prior to injection into mice.
Group Prion Treatment Concentration Time Temp. Inactivation
Untreated 1:100 RML None NA NA NA No
Negative control Saline None NA NA NA No
Heated control 1:100 RML None NA NA NA Yes
Subtilisin 309 high 1:100 RML Subtilisin 309 138mAU/ml 14h 55 ◦C Yes
Subtilisin 309 med 1:100 RML Subtilisin 309 70mAU/ml 14h 20 ◦C Yes
Subtilisin 309 low 1:100 RML Subtilisin 309 30mAU/ml 14h 20 ◦C Yes
Subtilisin 309-v 1:100 RML Subtilisin 309-v 138mAU/ml 14h 20 ◦C Yes
Hypochlorite 1:100 RML Household bleach 40% (v/v) 1h 20 ◦C No
Autoclave 1:100 RML Autoclave NA 20min 134 ◦C No
All treatment groups were injected with 1:100 final concentration of infectious brain homogenate the negative control group which was given phosphate buffered saline.
Heat inactivation was 85 ◦C for 35min.
tion buffers, and readily achievable environmental conditions in
reactions toproteolytically degradePrPres. Therefore, subtilisin 309,
manufactured under the commercial name Savinase (Novozymes,
Bagsvaerd, Denmark), and subtilisin 309-v (Tindbaek et al., 2004),
an engineered modification of subtilisin 309 to maintain high pro-
teolytic activity at lower temperatures, were used at commercially
economical enzyme concentrations, slightly basic digestion con-
ditions and low temperatures. The conditions tested reveal that
enzymatic degradation of PrPres will be difficult to achieve unless
high; pH, enzyme concentrations, and temperatures are used.
2. Materials and methods
2.1. Enzymes
Two enzymes: subtilisin 309 of Bacillus clausii (subtilisin 309),
and a variant wherein valine at position 66 and serine at position
104 were substituted with alanine (subtilisin 309-v) to enhance
proteolytic activity at lower temperature were used in this study to
investigate enzymatic PrPres decontamination. Novozymes (Den-
mark) provided both enzymes. All enzyme units are reported as
Anson units per ml (AU/ml).
2.2. ELISA and Western blot detection of PrPres
To evaluate chronic wasting disease (CWD) enzyme digestion
conditions mule deer (Odocoileus hemionus) brain (Colorado Divi-
sion of Wildlife, Fort Collins, CO) that had a predetermined PrPres
concentration of 3g PrPres/gram (Raymond et al., 2000) was
used. Brain material was dounce homogenized at a 1:5 (w/v) con-
centration in water. Digestion reactions were carried out with
6.0×10−5g PrPres in 25mM Bicarbonate buffer at the indicated
pH in a total volume of 100l and incubated at 20 ◦C for 14h.
Enzyme was heat inactivated at 85 ◦C for 35min. Untreated con-
trol was carried out in a parallel reaction in Delbecco’s phosphate
buffered saline. Evaluation of the remaining immunoreactive PrPres
was evaluated at the Colorado State University Veterinary Diag-
nostic Laboratory using the BioRad procedure and BSE test kit
(BioRad, Hercules, CA) under validated standard operating proce-
dures approved by the USDA. All samples were run in triplicate
wells. CWD brain homogenate used in Western blot samples were
treated as described above except no subtilisin enzymewas added.
After incubation and inactivation 20l of samples were mixed
with 5l 5× gel loading buffer heat denatured and resolved on
4–20% gradient SDS-PAGE gels (Invitrogen, CA). Resolved samples
were transferred to polyvinylidene fluoride membrane (Millipore,
Billerica, MA, USA). Membranes were blocked and with 5% (w/v)
powdered milk in TBST (25mM Tris, 140mM NaCl, 3mM KCl,
0.05% Tween-20, pH 8.0). Primary antibody Bar 224 was added
(SpiBio, Montigny-Le-Bretonneuxx-Cedex, France) at 1/2000 dilu-
tion in TBST and 1% milk for 2h at room temperature. Blots were
washed 3× 5min and exposed to a 1/10,000 dilution of secondary
antibody (Antimouse HRP conjugated, Pierce, Rockford, IL, USA) for
1h. Blots were washed as above and samples were visualized by
chemiluminescence (Super Signal, Pierce, Rockford, IL, USA) and
photographed with a CCD camera.
2.3. Digestion of material for in vivo mouse experiment
Rocky Mountain Laboratory mouse-adapted scrapie strain was
used (Rocky Mountain Laboratories, Hamilton, MT) for all in vivo
testing. End-stage clinical positive brain was homogenized in PBS
at 1:10 (w/v) using a hand held dounce. Homogenized brain mate-
rial was further diluted in PBS to a final concentration of 1:100
(w/v). Treatment conditions used for decontamination are outlined
in Table 1.
2.4. Mouse inoculation and monitoring
C57Bl/6 mice (Hilltop Laboratory Animals, Hilltop, PA) were
injected with 50l of treated or control brain homogenate in to
the peritoneal cavity. The peritoneal route of challenge was chosen
due to toxicity concerns of intracranial injections that could result
from hypochlorite and residual enzyme matrix. Mice were mon-
itored for kyphosis, ataxia, stiff tail, lack of grooming, emaciation,
extreme lethargy/excitability; counting one point for each sign that
was suspect, and two points for each distinct sign.When the condi-
tionof amouse resulted ina scoreof≥8points, orwhenamousehad
≥6 points for 3 days, themouse was euthanized (hereafter referred
to as death for simplicity). All animals were sacrificed at 18months
after challenge inoculation. Allmouse experimentswere conducted
with the approval of the National Wildlife Research Center animal
care committee and adherence to animal. welfare guidelines.
2.5. Statistical analysis
Survival analysis was performed on mouse survival data using
the Log Rank test. Calculations were performed according to
the British Medical Journal online survival analysis statistics
instructions (eBMJ – Statistics at Square One: Survival analy-
Table 2
Survival of mice inoculated with treated mouse-adapted scrapie.
Treatment Group Total Died Range Mean± S.D. P-value
Untreated 5 5 213–213 213 ± 0 .33
Saline control 21 0 – – <.0001
Heated control 21 20 220–262 234 ± 11 –
Subtilisin 309 138mAU/ml 21 9 239–261 248 ± 8 <.0001
Subtilisin 309 70mAU/ml 18 16 224–253 233 ± 8 .58
Subtilisin 309 30mAU/ml 21 19 223–249 233 ± 8 .71
Subtilisin 309-v 138mAU/ml 16 13 227–255 241 ± 9 .028
Hypochlorite 21 0 – – <.0001
Autoclave 21 0 – – <.0001
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Fig. 1. Kaplan–Meyer survival curves of mice injected with treated PrPres. Days 190 to 270 post inoculation, the times when mice succumbed to disease, are shown. No mice
died of prion disease between 270 days and the 18-month termination of the study.
sis [http://bmj.bmjjournals.com/statsbk/12.shtml]). Excel (version
2002; Microsoft Corporation) was used to obtain P-values from the
chi-squared values and calculate standard errors on ELISA results.
3. Results
3.1. In vivo testing of enzymatic destruction of PrPres
The different treatment groups and the conditions for PrPres
digestion used in the mouse bioassay are detailed in Table 1. All
mice injected with untreated RML scrapie brain homogenate were
dead by 215 days after inoculation, which is typical for a high-
infectivity titer RML prion strain given intraperitoneally (Pilon et
al., 2007). Table 2 presents the survival statistics. Surprisingly,
the heat treatment used to inactivate the enzymes prior to injec-
tion led to a 21-day increase in mean survival time relative to
the untreated control. Low (30mAU/ml) andmedium (70mAU/ml)
dose subtilisin 309 treatments did not statistically improve sur-
vival over heated control; although, an additional animal survived
to the study endpoint for both the low and medium does subtil-
isin 309 treatment groups relative to the heated control. Treatment
with subtilisin 309-v led to longer survival than heating alone with
an increase in the mean time to sacrifice by 7 days, whilst an
increase of 14% in survivorship was observed (Fig. 1). The most
effective enzyme digestion condition (P<0.0001) was subtilisin
309 at 138mAU/ml, 55 ◦C, and pH 7.9 with 14h of treatment time.
Treatment under these conditions reduced PrPres infectivity that
eliminated disease in 57% of the mice, representing a 52% increase
in survivorship compared to theheated control. Two recommended
methods for PrPres decontamination, hypochlorite (40% bleach)
treatment and autoclaving (134 ◦C, 20min), eliminated all measur-
able PrPres infectivity in this bioassay and none of themice in these
groups died of prion disease by 18 months when the study was
terminated.
3.2. Digestion of PrPres (CWD) at alkaline pH
Since subtilisin enzymes are alkaline proteases and have
increased activity at higher pH, and the fact that PrPres decontam-
ination procedures are needed to treat paddocks/environments to
eliminate chronic wasting disease (CWD) PrPres infectivity, an in
vitro ELISA assay was done to test the effect of pH and enzyme con-
centrations on PrPres digestion using CWD infectedmule deer brain
homogenate. As expected, pH has a very large influence on subtil-
isin activity and prion degradation as shown in Fig. 2. Absorbance
readings were 4-fold lower at pH 10.5 compared to pH 8.2 when
the final concentration of enzyme activity was 0.6mAU/ml for sub-
tilisin 309. The strong pH dependence on digestion efficiency is
reduced at higher enzyme concentration, with only a 2-fold and
1.5-fold reduction in ELISA absorbance observed between the high
and low pH PrPres digestion reactions at 6.0 and 60mAU/ml respec-
tively. The performance of subtilisin 309-v was less effective across
all pH values as shown in Fig. 2B. A reduction of immunoreactive
signal and CWD prion degradation is expected due to pH effects
alone. Therefore a Western blot was run to visualize the qualita-
tive pH dependence on PrPres and is shown in Fig. 2C. The results
show that pH alone reduces the immunoreactive signal by signifi-
Fig. 2. (A) pH effects on subtilisin 309 and (B) subtilisin 309-vPrPres degrading
activity measured by BioRad BSE ELISA and (C) Western blot pH dependence on
immunoreactive signal. The results are expressed as percent of untreated positive
brain due to the additive effects of increased pH on immunoreactivity and PrPres
degradation. CWD positive mule deer brain was incubated at 20 ◦C for 14h. All sam-
ples water treated at 85 ◦C for 35min prior to ELISA to inactive remaining enzymes.
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cant amounts. Densitometry measurements of Western blot signal
showed a decrease of 30% and 60% at pH=9.0 and 10.2 respectively
relative to pH=8.2.
4. Discussion
Our choice of bioassay conditions were largely defined by two
considerations: (1) conditions had to be mild, for use on sensi-
tive equipment or in environments where high pH may destroy
microbes important for ecology; (2) enzymeconcentrationsneeded
to be held relatively low so decontamination methods could be
applied economically by the end-user. To this end, even though
PrPres digestion conditions for the bioassay were chosen based
on loss of immunoreactivity in vitro (data not shown), no signif-
icant difference was observed in survivorship between subtilisin
309 PrPres digestions using 30 or 70mAU/ml and the survivorship
that was achieved by heating the homogenate to 85 ◦C for 35min.
Indeed, even the simple heating of PrPres increased survivorship by
18 days relative to the untreated control a result that was wholly
unexpected. However, the delay in end-stage clinical symptoms is
not without precedence, as a similar extension in life span upon
heating of PrPres strains was observed by Taylor et al. (2002). The
observed increase in lifespanwas hypothesized to occur in the cited
paper due to an alteration the structure PrPres strains that results
in alternative processing routes by the body compared to unheated
PrPres strains.
A statistically significant increase in survivorship was observed
when enzyme concentration was increased and a higher digestion
temperature was used. An infectious dose titration performed at
RockyMountain Laboratories using the same prion strain and route
of challenge in C57Bl/10mice (Priola andWard, personal communi-
cation) showed no deaths in mice inoculated with a 1:106 dilution
of infectious brain material. Our high concentration subtilisin 309
treatment showed a higher percent survival than the 1:105 brain
homogenate dilution point, indicating that our treatment was less
thanone logaway fromremoval of infectivity asobservedbyclinical
end-stage bioassay. Although it must be noted that the major his-
tocompatibility complex difference in the congenic strains of mice
may alter susceptibility to PrPres challenge, it is probable that the
pattern of response to decreasing doses is similar.
In addition to mouse bioassay, digestions using a CWD PrPres
strain with endpoint ELISA readout were conducted with pH and
enzyme concentration as variables. The result of the in vitro assay
showed the expected pH dependence on enzyme activity with
increasing alkalinity. The observation that pH dependent dose
response greatly decreases with increasing enzyme concentration
suggests that a resistant core of PrPres infectivity may exist below
the limit of quantitation (LOQ) of the ELISA assay, as rawabsorbance
is still slightly above background. As others have observed, in vitro
results are not predictive of in vivo results (Jackson et al., 2005;
Kocisko et al., 1995). Therefore, to conclude if the conditions used
in our in vitro digestions conditions removed all detectable CWD
PrPres infectivity, a bioassay using transgenic cervidized mice will
be required. Of note is the fact that the observed decrease in PrPres
dependent ELISA signal is additive with both enzyme concentra-
tion and increasing pH playing a critical role in decontamination
reactions (Fig. 3). Western blot analysis of the effect of pH on PrPres
quality and quantity did indicate significant alterations in PrPres
levels.
The results presented herein reveal that enzymatic digestion at
near neutral pH, low activity, and moderate temperatures is not a
viable option for PrPres decontamination. If optimum alkaline pH,
high enzyme concentrations and elevated temperatures are used,
PrPres decontaminationmay be possible, although the broad-based
practicality from an economic and operational standpoint would
likely be limited. For enzymatic degradation of PrPres to be a use-
ful tool, significant improvements are needed. For the particular
enzymes used in this study, increasing pH may be a simple and
effective improvement. Indeed, in vitro results show that increas-
ing the pH of the digestion buffer as little as 1.0–1.5 pH units can
dramatically improve the enzymatic digestion of PrPres. In addi-
tion, additives such as detergents or chaotropic salts could also
improve the enzymatic digestion of PrPres and allow for viable and
economical PrPres decontamination method.
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